Detail akcie Rafael Hlds-B WI Rg online

Business Summary: Rafael Holdings, Inc. is a biotechnology company. The Company holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. It also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. It holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.
Financial Summary: BRIEF: For the nine months ended 30 April 2025, Rafael Holdings Inc revenues increased 20% to $567K. Net loss decreased 38% to $18.4M. Revenues reflect Healthcare segment increase from $0K to $243K, Real Estate segment increase of 10% to $231K. Lower net loss reflects Healthcare segment loss decrease of 87% to $12.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.24 to -$0.75.